Contrast-enhanced whole-heart coronary MRA using Gadofosveset 3.0 T versus 1.5 T.
ABSTRACT To compare contrast-enhanced coronary magnetic resonance angiography (MRA) at 3.0 T with the same technique performed at 1.5 T using the contrast agent gadofosveset.
In this prospective randomized study, 19 healthy male volunteers (mean age 28 years, mean weight 79.8 kg), after signing informed consents, underwent contrast-enhanced inversion recovery three-dimensional fast low angle shot (FLASH) MRA at 1.5 and at 3.0 T. Prospective electrocardiogram-triggering was combined with adaptive respiratory gating. For contrast-enhanced images, the intravascular contrast agent gadofosveset was used. Acquisition time, signal-to-noise ratio (SNR) of coronary blood, contrast-to-noise ratio (CNR) between coronaries and adjacent myocardium or epicardial fat and image quality were analyzed for statistical differences by using a two-tailed paired-sample t-test. The ratio calculations were based on measurements performed on the raw data and the image quality was blinded and independently evaluated by two experienced radiologists using a five-point scale.
The mean values for the acquisition time were 14.58 +/- 0.1 minutes at 1.5 T and 16.40 +/- 0.2 minutes at 3.0 T. Overall SNR of all evaluated coronary segments proved higher at 3.0 T compared to 1.5 T (74.0 +/- 42.1 at 3.0 T vs. 50.2 +/- 20.2 at 1.5 T, P = .04). Overall CNR between coronaries and myocardium was significantly increased at 3.0 T in comparison to 1.5 T (40.1 +/- 21.9 at 3.0 T vs. 24.4 +/- 17.2 at 1.5 T, P = .01). Between the two methods, no significant difference in overall CNR between coronaries and epicardial fat was observed (P = .08, NS). The 3.0 T MRA demonstrated superior overall image quality with respect to 1.5 T (2.28 +/- 0.71 at 3.0 T vs. 1.92 +/- 0.38 at 1.5T, P = .004).
The use of higher field strength, 3.0 T instead of 1.5 T, resulted in similar CNR between coronaries and epicardial fat, higher SNR values and CNR between blood and myocardium, as well as an improved overall image quality, when gadofosveset in combination with electrocardiogram and respiratory triggering for coronary MRA was used.
- SourceAvailable from: onlinelibrary.wiley.com[Show abstract] [Hide abstract]
ABSTRACT: This study was performed to determine the best concentration of gadofosveset at 1.5 and 3 T MRI for quantitative myocardial perfusion analysis. 18 healthy volunteers have been examined at a 1.5 and a 3 T MRI system assigned to one of three dose groups: low dose (0.00375 mmol/kg), medium dose (0.0075 mmol/kg), high dose (0.0150 mmol/kg). A T1-weighted saturation recovery turboFLASH sequence with parallel imaging was used. Two perfusion scans were performed for each field strength and volunteer. Peak signal-to-noise-ratio, maximum contrast-enhancement-ratio and myocardial blood flow (MBF) were calculated. MBF values were significantly higher at 1.5 T in the medium and the high dose groups than in the low dose group (p < 0.001). Higher MBF values could be found at 3 T for the second perfusion scan in the medium and both perfusion scans in the high dose group compared to the low dose group. Optimal dose of gadofosveset for quantitative perfusion analysis at 1.5 T is 0.00375 mmol/kg as higher doses caused overestimation of the MBF. At 3 T 0.0075 mmol/kg seems to be the best dose for a single perfusion scan, while for a second perfusion scan MBF may be overestimated.The international journal of cardiovascular imaging 06/2013; · 2.15 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Gadolinium enhanced coronary magnetic resonance angiography (MRA) at 3 T appears to be superior to non-contrast methods. Gadofosveset is an intravascular contrast agent that may be well suited to this application. The purpose of this study was to perform an intra-individual comparison of gadofosveset and gadobenate for coronary MRA at 3 T. In this prospective randomized study, 22 study subjects [8 (36 %) male; 27.9 ± 6 years; BMI = 22.8 ± 2 kg/m(2)] underwent two studies using a contrast-enhanced inversion recovery three-dimensional fast low angle shot MRA at 3 T. The order of contrast agent administration was varied randomly, separated by an average of 30 ± 5 days, using either gadobenate dimeglumine (Gd-BOPTA; Bracco, 0.1 mmol/Kg) or gadofosveset trisodium (MS-325; Lantheus Med, 0.03 mmol/Kg). Acquisition time, signal-to-noise ratio (SNR) of coronary vessels and contrast-to-noise ratio (CNR) were evaluated. Of 308 coronary arteries and veins segment analyzed, overall SNR of coronary arteries and veins segments were not different for the two contrast agents (132 ± 79 for gadofosveset vs. 135 ± 78 for gadobenate, p = 0.69). Coronary artery CNR was greater for gadofosveset in comparison to gadobenate (73.5 ± 46.9 vs. 59.3 ± 75.7 respectively, p = 0.03). Gadofosveset-enhanced MRA images displayed better image quality than gadobenate-enhanced MRA images (2.77 ± 0.61 for gadofosveset vs. 2.11 ± 0.51, p < .001). Inter- and intra-reader variability was excellent (ICC > 0.90) for both contrast agents. Gadofosveset trisodium appears to show slightly better performance for coronary MRA at 3 T compared to gadobenate.The international journal of cardiovascular imaging 03/2013; · 2.15 Impact Factor
- Current Cardiovascular Imaging Reports 10/2013; 6(5).